VCMCVC Market Cap
Menu

Element Biosciences valuation, funding and investors

elementbiosciences.com ↗LinkedIn ↗

Element Biosciences works in sequencing platform manufacturing, based in San Diego, United States. Founded in 2017, it has about 448 employees.

Biotechnology Series E
VALUATION · TODAY
$2.42B +18% after Series E
Range $1.45B – $4.35B · Grade B
TODAY
+12 MO
$1.00B
$2.00B
$3.00B
$4.00B
$5.00B
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series A $15.0M
Series B $80.3M
Series C $276M
Series D $277M
Series E $175M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY448 employees
+7%6m growth
+9%1y growth
+24%2y growth
250
500
Data from Jan 2021
TODAY
Predicted in 1 yr $2.86B +18% vs today
Predicted next raise $315M if a round comes
Winding-down probability 0%
Last round
Series E · $175M · Jun 2026
Valuation at last round
$2.19B · implied
Headcount
448 · flat
Grade
B
Founded
2017
How VCMC values companies →

Element Biosciences valuation today

VCMC values Element Biosciences at $2.4B today, with a range of $1.4B to $4.4B and a grade of B. The valuation starts from its last funding round, a Series E round in Jun 2026.

Valuation by date (124 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Element Biosciences: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2017$6.60M$2.40M – $18.1M$9.05M (+37%)before first round–unknownD0%
1 Feb 2017$6.78M$2.47M – $18.6M$9.29M (+37%)before first round–unknownD0%
1 Mar 2017$6.94M$2.53M – $19.1M$9.52M (+37%)before first round–unknownD0%
1 Apr 2017$7.13M$2.60M – $19.6M$9.78M (+37%)before first round–unknownD0%
1 May 2017$7.32M$2.67M – $20.1M$10.0M (+37%)before first round–unknownD0%
1 Jun 2017$7.52M$2.74M – $20.7M$10.3M (+37%)before first round–unknownD0%
1 Jul 2017$7.72M$2.81M – $21.2M$10.6M (+37%)before first round–unknownD0%
1 Aug 2017$7.93M$2.89M – $21.8M$10.9M (+37%)before first round–unknownD0%
1 Sep 2017$8.14M$2.96M – $22.4M$11.2M (+37%)before first round–unknownD0%
1 Oct 2017$8.36M$3.04M – $23.0M$11.5M (+37%)before first round–unknownD0%
1 Nov 2017$8.58M$3.12M – $23.6M$11.8M (+37%)before first round–unknownD0%
1 Dec 2017$8.81M$3.21M – $24.2M$12.1M (+37%)before first round–unknownD0%
1 Jan 2018$9.05M$3.29M – $24.9M$12.4M (+37%)before first round–unknownD0%
1 Feb 2018$9.29M$3.38M – $25.5M$12.7M (+37%)before first round–unknownD0%
1 Mar 2018$9.52M$3.47M – $26.2M$13.1M (+37%)before first round–unknownD0%
1 Apr 2018$9.78M$3.56M – $26.9M$13.4M (+37%)before first round–unknownD0%
1 May 2018$10.0M$3.65M – $27.6M$13.8M (+37%)before first round–unknownD0%
1 Jun 2018$10.3M$3.75M – $28.3M$14.1M (+37%)before first round–unknownD0%
1 Jul 2018$10.6M$3.85M – $29.1M$14.5M (+37%)before first round–unknownD0%
1 Aug 2018$10.9M$3.96M – $29.9M$14.7M (+35%)before first round–unknownD0%
1 Sep 2018$11.2M$4.06M – $30.7M$14.8M (+32%)before first round–unknownD0%
1 Oct 2018$11.5M$4.17M – $31.5M$14.9M (+30%)before first round–unknownD0%
1 Nov 2018$11.8M$4.28M – $32.3M$15.1M (+28%)before first round–unknownD0%
1 Dec 2018$12.1M$4.40M – $33.2M$15.2M (+26%)before first round–unknownD0%
1 Jan 2019$12.4M$4.52M – $34.1M$15.3M (+24%)before first round–unknownD0%
1 Feb 2019$12.7M$4.64M – $35.0M$15.5M (+21%)before first round–unknownD0%
1 Mar 2019$13.1M$4.75M – $35.9M$15.6M (+19%)before first round–unknownD0%
1 Apr 2019$13.4M$4.88M – $36.8M$15.7M (+17%)before first round–unknownD0%
1 May 2019$13.8M$5.01M – $37.8M$15.9M (+15%)before first round–unknownD0%
1 Jun 2019$14.1M$5.15M – $38.8M$16.0M (+13%)before first round–unknownD0%
19 Jun 2019$83.5M$54.8M – $228M$150M (+80%)after a round–unknownC0%
1 Jul 2019$85.1M$54.8M – $228M$150M (+76%)after a round–unknownC0%
1 Aug 2019$89.4M$54.8M – $228M$150M (+68%)after a round–unknownC0%
1 Sep 2019$94.0M$54.8M – $228M$150M (+60%)after a round–unknownC0%
1 Oct 2019$98.7M$54.8M – $228M$150M (+52%)after a round–unknownC0%
1 Nov 2019$104M$54.8M – $228M$150M (+45%)after a round–unknownC0%
1 Dec 2019$109M$54.8M – $228M$150M (+38%)after a round–unknownC0%
1 Jan 2020$114M$54.8M – $228M$150M (+31%)after a round–unknownC0%
10 Jan 2020$333M$234M – $708M$499M (+50%)after a round–unknownB0%
1 Feb 2020$341M$234M – $708M$499M (+46%)after a round–unknownB0%
1 Mar 2020$352M$234M – $708M$499M (+42%)after a round–unknownB0%
1 Apr 2020$365M$234M – $708M$499M (+37%)after a round–unknownB0%
1 May 2020$377M$234M – $708M$499M (+32%)after a round–unknownB0%
1 Jun 2020$390M$234M – $708M$499M (+28%)after a round–unknownB0%
1 Jul 2020$403M$234M – $708M$499M (+24%)after a round–unknownB0%
1 Aug 2020$418M$234M – $708M$499M (+19%)after a round–unknownB0%
1 Sep 2020$432M$234M – $708M$499M (+15%)after a round–unknownB0%
1 Oct 2020$447M$234M – $708M$499M (+12%)after a round–unknownB0%
1 Nov 2020$462M$234M – $708M$499M (+8%)after a round–unknownB0%
1 Dec 2020$478M$234M – $708M$499M (+4%)after a round–unknownB0%
1 Jan 2021$495M$234M – $708M$499M (+1%)after a round80unknownB0%
1 Feb 2021$499M$227M – $708M$499M (0%)after a round80unknownB0%
1 Mar 2021$499M$218M – $708M$499M (0%)after a round80unknownB0%
1 Apr 2021$499M$208M – $708M$499M (0%)after a round80unknownC0%
1 May 2021$499M$200M – $708M$499M (0%)after a round80unknownC0%
1 Jun 2021$499M$191M – $708M$499M (0%)after a round80unknownC0%
30 Jun 2021$1.7B$1.2B – $3.1B$2.2B (+30%)after a round80unknownB0%
1 Jul 2021$1.7B$1.2B – $3.1B$2.2B (+30%)after a round80unknownB0%
1 Aug 2021$1.7B$1.2B – $3.1B$2.2B (+27%)after a round80unknownB0%
1 Sep 2021$1.7B$1.2B – $3.1B$2.2B (+24%)after a round80unknownB0%
1 Oct 2021$1.8B$1.2B – $3.1B$2.2B (+22%)after a round80unknownB0%
1 Nov 2021$1.8B$1.2B – $3.1B$2.2B (+19%)after a round80unknownB0%
1 Dec 2021$1.9B$1.2B – $3.1B$2.2B (+16%)after a round80unknownB0%
1 Jan 2022$1.9B$1.2B – $3.1B$2.2B (+14%)after a round80unknownB0%
1 Feb 2022$1.9B$1.2B – $3.1B$2.2B (+11%)after a round80unknownB0%
1 Mar 2022$2.0B$1.2B – $3.1B$2.2B (+9%)after a round80unknownB0%
1 Apr 2022$2.4B$1.5B – $3.9B$2.7B (+13%)after a round230growingB0%
1 May 2022$2.5B$1.5B – $3.9B$2.7B (+8%)after a round230growingB0%
1 Jun 2022$2.6B$1.5B – $3.9B$2.7B (+4%)after a round230growingB0%
1 Jul 2022$2.7B$1.5B – $3.9B$2.7B (0%)after a round230growingB0%
1 Aug 2022$2.7B$1.4B – $3.9B$2.7B (0%)after a round230unknownB0%
1 Sep 2022$2.7B$1.3B – $3.9B$2.7B (0%)after a round230unknownB0%
1 Oct 2022$2.7B$1.3B – $3.9B$2.7B (0%)after a round230unknownB0%
1 Nov 2022$2.7B$1.2B – $3.9B$2.7B (0%)after a round230unknownB0%
1 Dec 2022$2.7B$1.2B – $3.9B$2.7B (0%)after a round230unknownB0%
1 Jan 2023$2.7B$1.1B – $3.9B$2.7B (0%)after a round230unknownC0%
1 Feb 2023$2.9B$1.4B – $4.1B$2.9B (0%)after a round300upB0%
1 Mar 2023$2.9B$1.4B – $4.1B$2.9B (0%)after a round300upB0%
1 Apr 2023$2.9B$1.4B – $4.1B$2.9B (0%)after a round300upB0%
1 May 2023$2.9B$1.4B – $4.1B$2.9B (0%)after a round300upB0%
1 Jun 2023$2.9B$1.4B – $4.1B$2.9B (0%)after a round300upB0%
1 Jul 2023$2.9B$1.3B – $4.1B$2.9B (0%)after a round300upB0%
1 Aug 2023$2.9B$1.2B – $4.1B$2.9B (0%)after a round300upC0%
1 Sep 2023$2.9B$1.2B – $4.1B$2.9B (0%)after a round300upC0%
1 Oct 2023$2.9B$737M – $4.1B$2.9B (0%)after a round300unknownC0%
1 Nov 2023$2.9B$711M – $4.2B$2.9B (-3%)after a round320flatC0%
1 Dec 2023$2.9B$677M – $4.2B$2.8B (-3%)after a round320flatC0%
1 Jan 2024$2.9B$643M – $4.2B$2.8B (-4%)after a round320flatC0%
1 Feb 2024$2.9B$611M – $4.2B$2.8B (-5%)after a round320flatC0%
1 Mar 2024$2.9B$583M – $4.2B$2.8B (-5%)after a round320flatC0%
1 Apr 2024$3.0B$557M – $4.2B$2.8B (-5%)after a round330flatD0%
1 May 2024$3.0B$531M – $4.2B$2.8B (-6%)after a round330flatD0%
1 Jun 2024$3.0B$504M – $4.2B$2.8B (-6%)after a round330flatD0%
1 Jul 2024$2.9B$480M – $4.2B$2.8B (-7%)after a round330flatD0%
11 Jul 2024$1.0B$895M – $1.5B$1.3B (+30%)after a round330flatA0%
1 Aug 2024$1.0B$895M – $1.5B$1.3B (+28%)after a round360upA0%
1 Sep 2024$1.1B$895M – $1.5B$1.3B (+25%)after a round360upA0%
1 Oct 2024$1.1B$895M – $1.5B$1.3B (+22%)after a round360upA0%
1 Nov 2024$1.1B$895M – $1.5B$1.3B (+20%)after a round360upA0%
1 Dec 2024$1.1B$895M – $1.6B$1.4B (+18%)after a round380upA0%
1 Jan 2025$1.2B$895M – $1.6B$1.4B (+15%)after a round380upA0%
1 Feb 2025$1.2B$895M – $1.6B$1.4B (+13%)after a round390upA0%
1 Mar 2025$1.2B$895M – $1.6B$1.4B (+11%)after a round390upA0%
1 Apr 2025$1.3B$895M – $1.6B$1.4B (+8%)after a round390upA0%
1 May 2025$1.3B$895M – $1.6B$1.4B (+6%)after a round390upA0%
1 Jun 2025$1.3B$895M – $1.6B$1.4B (+3%)after a round390upA0%
1 Jul 2025$1.4B$895M – $1.6B$1.4B (+1%)after a round390upA0%
1 Aug 2025$1.4B$890M – $1.6B$1.4B (0%)after a round412upA0%
1 Sep 2025$1.4B$882M – $1.6B$1.4B (0%)after a round412upA0%
1 Oct 2025$1.4B$875M – $1.6B$1.4B (0%)after a round411upA0%
1 Nov 2025$1.4B$867M – $1.6B$1.4B (0%)after a round411upB0%
1 Dec 2025$1.4B$861M – $1.6B$1.4B (0%)after a round420upB0%
1 Jan 2026$1.4B$854M – $1.6B$1.4B (0%)after a round420upB0%
1 Feb 2026$1.4B$847M – $1.6B$1.4B (0%)after a round420upB0%
1 Mar 2026$1.4B$840M – $1.6B$1.4B (0%)after a round420upB0%
1 Apr 2026$1.4B$833M – $1.6B$1.4B (0%)after a round420upB0%
1 May 2026$1.4B$827M – $1.6B$1.4B (0%)after a round420upB0%
1 Jun 2026$1.4B$826M – $1.6B$1.4B (0%)after a round436upB0%
10 Jun 2026$2.2B$1.4B – $4.3B$2.8B (+30%)after a round436upB0%
1 Jul 2026$2.2B$1.4B – $4.3B$2.8B (+28%)after a round436upB0%
1 Aug 2026$2.3B$1.4B – $4.3B$2.8B (+25%)after a round436flatB0%
1 Sep 2026$2.3B$1.4B – $4.3B$2.8B (+22%)after a round436flatB0%
1 Oct 2026$2.4B$1.4B – $4.4B$2.9B (+20%)after a round448flatB0%
24 Oct 2026$2.4B$1.4B – $4.4B$2.9B (+18%)after a round448flatB0%

Key facts about Element Biosciences

Founded
2017
Headquarters
San Diego, United States
Employees
about 448 +9% in a year
Total raised
$823M
Funding rounds
5
Last round
Series E Jun 2026

Element Biosciences was founded in 2017 by Matt Kellinger, Michael Previte and Molly He.

Element Biosciences funding history

Element Biosciences has 5 funding rounds on record, from Jun 2019 to Jun 2026, $823M in total. The latest disclosed valuation is $1.03B post-money (Series D, Jul 2024).

  1. Series E 9 Jun 2026

    Led by Samsung Electronics.

    Sources: elementbiosciences.com, rna-seqblog.com, ventureburn.com and 2 more

    $175M

  2. Series D 10 Jul 2024

    Led by Wellington Management; with Samsung Electronics, Fidelity, Foresite Capital, T. Rowe Price Associates, Inc, Venrock.

    Sources: biopharmiq.com, elementbiosciences.com

    $277M

    $1.03B post-money

  3. Series C 29 Jun 2021

    With Janus Henderson Investors, Logos Capital, Meritech Capital, Morgan Stanley, T. Rowe Price, Fidelity Management, Foresite Capital, JS Capital Management, RA Capital, Venrock, Fidelity Management & Research Company.

    Sources: fiercebiotech.com

    $276M

  4. Series B 9 Jan 2020

    With Fidelity Management & Research Company, JS Capital LLC, Foresite Capital, Venrock.

    Sources: elementbiosciences.com, insideprecisionmedicine.com, gunder.com

    $80M

  5. Series A 18 Jun 2019

    Led by Foresite Capital, Venrock.

    Sources: elementbiosciences.com, finsmes.com

    $15M

Element Biosciences investors

16 investors have backed Element Biosciences; Foresite Capital, Venrock and Samsung Electronics and 1 more led at least one round.

  • Venrock lead, 4 rounds
  • Samsung Electronics lead, 2 rounds
  • Wellington Management lead
  • Fidelity Management & Research Company 2 rounds
  • Fidelity
  • Fidelity Management
  • Janus Henderson Investors
  • JS Capital LLC
  • JS Capital Management
  • Meritech Capital
  • Morgan Stanley
  • T. Rowe Price
  • T. Rowe Price Associates, Inc

What Element Biosciences does

Element Biosciences works in biotechnology, with 14 recorded offerings and customers in life sciences and biotechnology.

ELEMENT BIOSCIENCES, INC. is an American biotechnology company that develops and manufactures sequencing and multiomics platforms for research and diagnostic applications. The company provides genetic analysis tools, including DNA and RNA sequencing platforms, and offers proprietary technologies for sequencing and biological assay systems. Element Biosciences serves researchers and laboratories in the life sciences and biotechnology sectors, with operations in over 40 countries.

Description from Veridion's company data.

Products and services

  • Sequencing Platform Manufacturing
  • Multiomics Platform Development
  • Genetic Analysis Tool Development
  • Genomic Sequencing Solutions
  • RNA Sequencing Solutions
  • Biotechnology Platform Development
  • Scientific Discovery Enablement Services
  • Genetic Engineering Solutions
  • Life Science Product Distribution
  • Scientific Technology Innovation Services
  • Genomic Data Analysis Services
  • Biotechnology Application Development
  • Scientific Community Empowerment Services
  • Global Scientific Product Distribution

Markets

  • Life Sciences
  • Biotechnology

Technology

  • Avidite Base Chemistry™

Business model

  • Business-to-Business
  • Manufacturing
  • Enterprise

Industry codes (NAICS)

  • 334516 Analytical Laboratory Instrument Manufacturing 70% match
  • 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers 30% match

Questions about Element Biosciences

What is Element Biosciences worth?

Valuation $2.4B (range $1.4B to $4.4B), as of 24 Oct 2026. The last disclosed valuation was $1.03B (Series D, Jul 2024).

Has Element Biosciences raised money?

Element Biosciences has 5 funding rounds on record, from Jun 2019 to Jun 2026, $823M in total. The latest disclosed valuation is $1.03B post-money (Series D, Jul 2024).

Who has invested in Element Biosciences?

Foresite Capital, Venrock, Samsung Electronics, Wellington Management, Fidelity Management & Research Company and Fidelity, and 10 more. Lead investors include Foresite Capital, Venrock, Samsung Electronics and Wellington Management.

How many people work at Element Biosciences?

About 448, up 9% over the last year. Headcount grew from 80 in Jan 2021 to 448 in Sep 2026.

What does Element Biosciences do?

Element Biosciences works in biotechnology, with 14 recorded offerings and customers in life sciences and biotechnology. Its main offerings are sequencing platform manufacturing, multiomics platform development and genetic analysis tool development.

When was Element Biosciences founded, and where is it based?

Element Biosciences was founded in 2017 and is based in San Diego, United States. It has about 448 employees, up 9% over the last year.

How we value companiesReport an issue